Attached files
| file | filename |
|---|---|
| EX-10.38 - EXHIBIT 10.38 - ALBANY MOLECULAR RESEARCH INC | v460825_ex10-38.htm |
| EX-32.2 - EXHIBIT 32.2 - ALBANY MOLECULAR RESEARCH INC | v460825_ex32-2.htm |
| EX-32.1 - EXHIBIT 32.1 - ALBANY MOLECULAR RESEARCH INC | v460825_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - ALBANY MOLECULAR RESEARCH INC | v460825_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - ALBANY MOLECULAR RESEARCH INC | v460825_ex31-1.htm |
| EX-21.1 - EXHIBIT 21.1 - ALBANY MOLECULAR RESEARCH INC | v460825_ex21-1.htm |
| EX-10.39 - EXHIBIT 10.39 - ALBANY MOLECULAR RESEARCH INC | v460825_ex10-39.htm |
| EX-10.37 - EXHIBIT 10.37 - ALBANY MOLECULAR RESEARCH INC | v460825_ex10-37.htm |
| 10-K - 10-K - ALBANY MOLECULAR RESEARCH INC | v460825_10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Albany Molecular Research, Inc.:
We consent to the incorporation by reference in the registration statements on Form S-3 (Registration Nos. 333-178718, 333-200800, 333-213768, and 333-207247), and on Form S-8 (Registration Nos. 333-80477, 333-91423, 333-152169, 333-174973, 333-189219, and 333-205036) of Albany Molecular Research, Inc. (“the Company”) of our report dated March 16, 2017, with respect to the consolidated balance sheets of Albany Molecular Research, Inc. and subsidiaries as of December 31, 2016 and 2015, the related consolidated statements of operations, comprehensive loss, stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2016, and the related financial statement schedule, and the effectiveness of internal control over financial reporting as of December 31, 2016, which report appears in the December 31, 2016 annual report on Form 10-K of Albany Molecular Research, Inc.
Our report dated March 16, 2017, on the effectiveness of internal control over financial reporting as of December 31, 2016, contains an explanatory paragraph that management excluded from its assessment of the effectiveness of internal control over financial reporting as of December 31, 2016, Prime European Therapeuticals S.p.A.’s (the Acquired Business) internal control over financial reporting associated with assets representing 27% of consolidated total assets and revenues representing 23% of consolidated total revenues included in the consolidated financial statements of the Company as of and for the year ended December 31, 2016. Our audit of internal control over financial reporting of Albany Molecular Research, Inc. also excluded an evaluation of the internal control over financial reporting of the Acquired Business.
/s/ KPMG LLP
Albany, New York
March 16, 2017